3/3
10:05 am
tsha
Gene Therapy Market Competitive Landscape Report 2026: Comprehensive Insights About 180+ Companies and 200+ Drugs by Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]
Low
Report
Gene Therapy Market Competitive Landscape Report 2026: Comprehensive Insights About 180+ Companies and 200+ Drugs by Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]
3/3
08:03 am
tsha
Taysha Gene Therapies (TSHA) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $10.00 price target on the stock.
Low
Report
Taysha Gene Therapies (TSHA) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $10.00 price target on the stock.
2/6
08:00 am
tsha
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2/2
09:44 am
tsha
Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo's Support on Rett Syndrome Program Progress [Yahoo! Finance]
Low
Report
Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo's Support on Rett Syndrome Program Progress [Yahoo! Finance]
1/29
04:42 pm
tsha
Here's What Analysts Are Saying About Taysha Gene Therapies (TSHA) [Yahoo! Finance]
Low
Report
Here's What Analysts Are Saying About Taysha Gene Therapies (TSHA) [Yahoo! Finance]
1/14
02:21 pm
tsha
Taysha Gene Therapies Inc. (TSHA): A Promising Biotech on Rett Syndrome Drug Prospects [Yahoo! Finance]
Low
Report
Taysha Gene Therapies Inc. (TSHA): A Promising Biotech on Rett Syndrome Drug Prospects [Yahoo! Finance]
1/6
03:01 pm
tsha
Taysha Gene Therapies (NASDAQ:TSHA) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..
Low
Report
Taysha Gene Therapies (NASDAQ:TSHA) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..
1/6
02:33 pm
tsha
Taysha Gene Therapies (NASDAQ:TSHA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
Low
Report
Taysha Gene Therapies (NASDAQ:TSHA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
1/6
08:00 am
tsha
Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome
Medium
Report
Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome
1/5
08:42 am
tsha
Taysha Gene Therapies (NASDAQ:TSHA) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Medium
Report
Taysha Gene Therapies (NASDAQ:TSHA) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
1/3
01:08 am
tsha
Taysha Gene Therapies (NASDAQ:TSHA) was downgraded by analysts at
Wall S
Medium
Report
Taysha Gene Therapies (NASDAQ:TSHA) was downgraded by analysts at
Wall S
12/22
09:30 am
tsha
Is FDA Breakthrough Status For TSHA-102 Reshaping The Investment Case For Taysha Gene Therapies (TSHA)? [Yahoo! Finance]
Medium
Report
Is FDA Breakthrough Status For TSHA-102 Reshaping The Investment Case For Taysha Gene Therapies (TSHA)? [Yahoo! Finance]
12/22
08:36 am
tsha
Taysha Gene Therapies (TSHA): Revisiting Valuation After Breakthrough Rett Data and Bullish Analyst Upgrades [Yahoo! Finance]
Medium
Report
Taysha Gene Therapies (TSHA): Revisiting Valuation After Breakthrough Rett Data and Bullish Analyst Upgrades [Yahoo! Finance]
12/21
07:42 am
tsha
Taysha Gene (TSHA) Hovers Around Its 52-Week High As It Continues to Advance Rett Syndrome Program [Yahoo! Finance]
Medium
Report
Taysha Gene (TSHA) Hovers Around Its 52-Week High As It Continues to Advance Rett Syndrome Program [Yahoo! Finance]
12/13
01:10 am
tsha
Taysha Gene Therapies (NASDAQ:TSHA) was upgraded by analysts at
Wall Str
Low
Report
Taysha Gene Therapies (NASDAQ:TSHA) was upgraded by analysts at
Wall Str
12/5
04:05 pm
tsha
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)